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Abstract
Background: Into the 21st century, the conflation of high rates of chronic pain, systemic gaps in treatment
availability and access, and the arrival of potent new opioid medications (e.g., slow-release oxycodone) facilitated
strong increases in medical opioid dispensing in Canada. These persisted until post-2010 alongside rising opioid-
related adverse (e.g., morbidity/mortality) outcomes. We examine patterns, trends and determinants of opioid
dispensing in Canada, and specifically its 10 provinces, for the years 2005–2020.
Methods: Raw data on prescription opioid dispensing were obtained from a large national community-based
pharmacy database (IQVIA/Compuscript), converted into Defined-Daily-Doses/1,000 population/day for ‘strong’ and
‘weak’ opioid categories per standard methods. Dispensing by opioid category and formulations by province/year
was assessed descriptively; regression analysis was applied to examine possible segmentation of over-time strong
opioid dispensing.
Results: All provinces reported starkly increasing strong opioid dispensing peaking 2011–2016, and subsequent
marked declines. About half reported lower strong opioid dispensing in 2020 compared to 2005, with continuous
inter-provincial differences of > 100 %; weak opioids also declined post-2011/12. Segmented regression suggests
breakpoints for strong opioids in 2011/12 and 2015/16, coinciding with main interventions (e.g., selective opioid
delisting, new prescribing guidelines) towards more restrictive opioid utilization control.
Conclusions: We characterized an era of marked rise and fall, while featuring stark inter-provincial heterogeneity in
opioid dispensing in Canada. While little evidence for improvements in pain care outcomes exists, the starkly
inverting opioid utilization have been associated with extensive population-level harms (e.g., misuse, morbidity,
mortality) over-time. This national case study raises fundamental questions for opioid-related health policy and
practice.
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Introduction
The transition into the 21st century marked a turning
point for chronic pain and related opioid pharmacother-
apy in North America, and Canada specifically. There,
20–29 % of the gcomes in the populationeneral popula-
tion were estimated to experience chronic pain in the
early 2000s, however systemic gaps existed in access to
and/or effectiveness of available care [1, 2]. More
broadly, a vocal socio-medical movement had begun to
propagate chronic pain as a neglected ‘fifth vital sign’,
advocating for systematic expansions of improved treat-
ment and care [3, 4], including more generous utilization
of opioid pharmacotherapy options then generally con-
sidered “safe and efficacious” [1]. Among other barriers,
pharmacotherapeutic approaches to chronic pain care
were viewed as hindered by many physicians’ lack of
knowledge and/or hesitation to prescribe available opi-
oid medications for chronic pain [5, 6].
A number of concrete developments facilitated a pro-
found expansion of opioid pharmacotherapy for chronic
pain in the early 2000s in Canada. Sequential iterations
of national pain care guidelines (updated in 2002) rec-
ommended a wider-scale and more generous (e.g.,
higher doses/long-term) therapeutic utilization of opioid
analgesic medications for chronic pain [7]. In addition,
new and potent opioid formulations – most notably in-
cluding ‘slow-release’ oxycodone (e.g., Oxycontin) – had
become available and became widely utilized, alongside
other potent semi-/synthetic opioid medications (e.g.,
fentanyl, hydromorphone) that were increasingly and
more generously prescribed in both specialist and gen-
eral/community practice settings [8–10]. Particularly in
the case of Oxycontin, their rising utilization was dis-
tinctly boosted by pharmaceutical companies’ targeted
marketing strategies involving ‘peer educators’ (i.e., phys-
ician representatives) promoting expanded prescribing
[11, 12].
In these contexts, the population rate of controlled
total opioid dispensing in Canada - as reported by the
International Narcotics Control Board (INCB) - more
than tripled within just one decade, from 8,713 Stan-
dardized Defined Daily Doses [S-DDD] in 2000–2002 to
29,743 S-DDD in 2010-12 [13]. During this period,
Canada’s opioid dispensing rate climbed more steeply
than that of the United States (US), the nation featuring
the world’s highest opioid consumption rate; on this
basis, Canada rose to record the world’s second-highest
opioid consumption rate (after the US) [14]. By 2010,
more than one-in-five (20 %) of Canadian adults re-
ported annual use of pain-related opioid medications
[15].
While the benefits for therapeutic pain care quality
and outcomes from these extensive increases have
remained uncertain, they were associated with rising
adverse opioid-related (e.g., mortality and morbidity)
outcomes in the population, including increases in non-
medical opioid use and diversion, opioid-related hospi-
talizations, treatment admissions and poisoning fatalities
[15–17]. For example, in Ontario, 6 % of adults and 15 %
of high-school students reported non-medical opioid use
by 2010, opioid-related treatment admissions doubled
and opioid-related fatalities rose from 366 (2003) to 571
(2010), with approximately 40 % oxycodone-related [15,
18, 19]. By 2010, it was evident that a sort of ‘opioid cri-
sis’ involving extensive adverse health outcomes in the
population -- fuelled by the excessive availability and ad-
verse consequences of prescription opioids -- was
unfolding in Canada [8, 20, 21].
While government and other (e.g., medical/regulatory)
policy makers and stakeholders had undertaken little to
halt the growing opioid-related harms until then, a series
of multi-level interventions aiming to restrict opioid
availability and harms were implemented post-2010 [22].
Among them, slow-release oxycodone formulations were
delisted from most provincial formularies across Canada
in 2012 [23, 24]. Several provinces introduced (e.g., On-
tario in 2012) or ramped up their ‘prescription monitor-
ing’ systems including opioids in their scope [25, 26]. A
national stakeholder coalition tabled a strategic action
plan of proposed measures [2013] to reduce opioid-
related harms [27]. Select regulatory efforts aimed to in-
crease the use of ‘safer’ (e.g., tamper-resistant/abuse-de-
terrent) opioid formulations, and to limit high-dose
prescribing [23, 28]. Meanwhile, emerging scientific evi-
dence assumed an increasingly cautious and restrained
view on the effectiveness and safety of opioid pharmaco-
therapy especially for chronic pain care [29, 30]. Corres-
pondingly, new Canadian opioid prescribing guidelines
(2017), similar to recent US (CDC) counterparts
launched in 2016, presented a marked reversal from pre-
vious guideline versions and provided direction for a
generally much more restrained and cautious (‘last re-
sort’) approach to opioid pharmacotherapy utilization
and practice for pain care [31].
Following these interventions, on overall decline in
medical opioid utilization began to unfold. Canada’s
total opioid utilization peaked at 34,444 S-DDD in
2013-15, and substantively decreased to 19,629 S-
DDD (-43 %) by 2017-19 [13]. While prescription
opioid-related harms (e.g., poisoning fatalities)
remained generally steady, expanding availability and
use of illicit/synthetic opioid (e.g., fentanyl) products
started to shift and accelerate patterns especially of
non-medical opioid harms in the years since 2014/15
across Canada [32–34]. In 2018, the federal govern-
ment established of the Canadian Pain Task Force,
with a mandate to assess the state of pain and related
care practices and systems in Canada [35].
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Within these wider contexts, and building on previous
related examinations, the present study assesses overall
(quantitative & qualitative) patterns, trends and determi-
nants of medical opioid utilization in Canada and specif-
ically its 10 provinces for the period 2005–2020.
Methods
The primary data on prescription opioid dispensing in
Canada for the period 2005–2020 were derived and
computed based on information from the IQVIA
Canada Inc. (formerly QuintilesIMS/IMS Brogan) Com-
puscript database. This database monitors prescription-
based transactions for branded and generic medications
via a representative and stratified sample of about 6,500
(representing about 60 % of the total) retail pharmacies
across Canada [36, 37]. Monthly dispensing data is ag-
gregated to provincial totals using a patented geospatial
projection methodology, with an estimated sampling
error of 5–10 %. The Compuscript data do not include
non-prescription (e.g., ‘over-the-counter’ codeine) prod-
ucts, nor cover other (e.g., hospital-based) drug dispens-
ing, yet comprise the far majority (estimated 80 %+) of
total utilization. Similar dispensing data have been used
for other population-level pharmacoepidemiologic ana-
lyses [38, 39].
Based on previously applied methods, raw prescription
opioid dispensing information was obtained by yearly to-
tals for the 10 Canadian provinces (but not including the
three Canadian territories, which however only make up
< 0.5 % of the Canadian total population) of both the
numbers of prescriptions and units dispensed, opioid
molecule (codeine, fentanyl, hydrocodone, hydromor-
phone, meperidine, methadone, morphine, oxycodone,
tramadol), and product name (494 unique names in-
cluded), form and strength information. Data for the dif-
ferent opioid products were matched to defined daily
dose (DDD) estimates using the World Health Organiza-
tion’s Anatomical Therapeutic Chemical classification
and DDD measurement methodology, defining DDDs as
the “… assumed average maintenance dose per day for a
drug used for its main indication in adults” [40]. DDD
are a standard metric commonly used for comparative
drug utilization analysis [41, 42]. Combined with yearly
provincial population estimates (obtained from Statistics
Canada [43]) the total opioid dispensing data was con-
verted to annual DDDs/per 1,000 population/per day
(DDD/1,000/day) estimates for the 10 provinces and
Canada total, and furthermore categorized into “strong
opioids” (i.e., including fentanyl, hydrocodone, hydro-
morphone, meperidine, morphine, and oxycodone) and
“weak opioids” (i.e., codeine) generally following the
WHO ‘analgesic ladder’ [44, 45]. Methadone, while de-
fined as a strong opioid, was excluded from the analyses
since it is primarily used for addiction (i.e., opioid
maintenance) treatment, and its dispensing practices are
inconsistent and do not allow for comparable estimates
across Canada [37].
Database design and data manipulation was conducted
using the R software package, including data plotting for
visualization [46]. For descriptive analyses, first, we ex-
amined the annual dispensing levels of “strong” (includ-
ing main individual formulations) and “weak” (codeine)
opioid products for Canada and the provinces, 2005–
2020. Second, we computed the intra-provincial ranges
of highest and lowest annual strong opioid dispensing
values for the study period. Third, towards assessing sig-
nificant over-time changes in strong opioid dispensing
in Canada, we applied a segmented (or ‘broken stick’) re-
gression analysis [47]. This regression-based method
partitions the independent variable into intervals and fits
corresponding straight-lines to data interval-subsets
(here the 16 annual datapoints of strong opioid dispens-
ing), while identifying possible inter-segmental ‘break-
points’ [48, 49]. Akaike information criterion (AIC)
values were computed to assess the quality-of-fit for
each model. For these analyses, the R package ‘seg-
mented’ was used.
Results
Strong opioids (total) [see Fig. 1 for data visualization]
In 2005, the lowest strong opioid dispensing rate was re-
ported by Manitoba (MN;3.9 DDD/1,000/day), and the
highest by Ontario (ON;10.1 DDD/1,000/day), translat-
ing into an inter-provincial range of difference of 159 %.
Between 2005 and 2011, each of the provinces reported
substantive increases in their annual rates of strong opioid
dispensing, with individual provinces’ respective opioid
dispensing levels peaking sometime between 2011 and
2016 as follows: British Columbia (BC), Alberta (AB), MN,
ON (2011); Nova Scotia (NS), Prince Edward Island (PEI;
2013); Saskatchewan (SK;2014); New Brunswick (NB),
Newfoundland (NL;2015); and Quebec (QC;2016). The
highest ‘peak’ value for opioid dispensing was reported by
ON (14.2 DDD/1,000/day), and the lowest ‘peak’ value by
QC (6.6 DDD/1,000/day), indicating a total inter-
provincial range of difference of 115 % for ‘peak’ levels.
Following their respective ‘peak’ level years, each of
the provinces reported decreases in strong opioid dis-
pensing, declining to - with the exception of two prov-
inces (BC & PEI) – lowest post-peak level of strong
opioid dispensing in 2020. ON reported the proportion-
ally greatest decrease between its respective ‘peak’ level
year in strong opioid dispensing (2011) and 2020
(-54.9 %) whereas PEI (2016–2020) had the correspond-
ingly smallest decrease (-17.8 %). In 2020, the lowest opi-
oid dispensing rate was report by MN (4.6 DDD/1,000/
day), and the highest rate by NB (9.0 DDD/1,000/day),
translating into an inter-provincial range of difference of
Jones et al. Substance Abuse Treatment, Prevention, and Policy           (2021) 16:65 Page 3 of 11
96 %. Four provinces reported same, or lower strong opi-
oid dispensing levels in 2020 compared with 2005.
For intra-provincial variation in annual strong opioid
dispensing, NB indicated the smallest range (49 %) and
NL indicated the largest range (126 %) over the observa-
tion period (2005–2020) (see Table 1).
Strong opioids (individual formulations) [see Fig. 2 for
data visualization]
For main individual strong opioid formulations, vary-
ing trends and patterns were observed by province.
For fentanyl, all provinces reported increases in dis-
pensing until 2014/2015 which then inverted to vary-
ing levels of decreases. In any given year, the inter-
provincial levels of fentanyl dispensing varied by at
least 100 %; half the provinces reported lower fentanyl
dispensing rates in 2020 compared to 2005. Hydroco-
done has been dispensed almost exclusively in ON
and, at much lower levels, in QC; its utilization in
ON was stable until 2011, and then steeply dropped.
Hydromorphone (similar to fentanyl) dispensing in-
creased in all provinces to 2015/2016, and subse-
quently inverted to decrease. While in any given year,
hydromorphone dispensing levels inter-provincially
varied by at least 100 %, each province reported
higher hydromorphone dispensing in 2020 as com-
pared with 2005. While some provinces reported in-
creases in morphine dispensing in the early years of
observation, other reported mostly decreasing trends;
half the provinces indicated lower morphine dispens-
ing levels in 2020 compared with 2005. BC is a noted
outlier for both hydromorphone and morphine dis-
pensing, in that it features marked recent increases in
dispensing for both recent opioid drugs; its morphine
utilization in 2020 is the highest for the total study
period. For oxycodone, most provinces reported strong
dispensing increases (most of them peaking in 2011)
which subsequently inverted to substantive decreases.
In each year, the inter-provincial dispensing range for
oxycodone differed by at least 200 %, while the major-
ity of provinces reported lower oxycodone dispensing
levels in 2020 compared with 2005.
Fig. 1 Annual ‘strong opioid’ utilization in DDD/1,000 population/day by province and Canada total, 2005–2020
Table 1 Intra-provincial ranges and percent differences in ‘strong
opioid’ utilization, provinces and Canada total, 2005–2020
DDD/1000/Day: Years 2005–2020
Province Minimum Maximum Difference (%)
BC 5.1 10.1 98.3 %
AB 5.9 10.5 76.2 %
SK 5.5 11.5 108.8 %
MN 3.9 7.9 101.7 %
ON 6.4 14.2 123.2 %
QC 4.2 6.6 58.3 %
NB 7.6 11.3 49.2 %
NS 7.8 13.3 69.9 %
PEI 5.9 10.7 82.0 %
NL 5.4 12.2 126.1 %
CA 6.2 10.8 74.1 %
Abbreviations: BC British Columbia, AB Alberta, SK Saskatchewan, MN
Manitoba, ON Ontario, QC Quebec, NB New Brunswick, NS Nova Scotia, PEI
Prince Edward Island, NL Newfoundland, CA Canada
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Weak opioids [see Fig. 2 for data visualization]
The majority of provinces reported relatively steady levels
in weak opioid (codeine) dispensing with most peak levels
in 2011/2012; subsequently, weak opioid dispensing
declined in all provinces, and each province except one
(SK) reported lower weak opioid dispensing in 2020 com-
pared with 2005. In each year, the inter-provincial range
of weak opioid dispensing rates differed by at least 300 %.
Fig. 2 Annual utilization of individual opioid formulations in DDD/1,000 population/day by province and Canada total, 2005–2020
Jones et al. Substance Abuse Treatment, Prevention, and Policy           (2021) 16:65 Page 5 of 11
Multilinear (segmented regression) analysis [see Fig. 3 for
results visualization]
Visual inspection of the over-time pattern for strong
opioid dispensing (see above) for Canada total suggests
an overall non-linear inversion shape, yet it is unclear
whether this may involve additional segments. On this
basis, the segmented regression analysis confirmed a
strictly linear model to be not statistically significant (ad-
justed R-square: -0.05). A four-segment model (using
possible breakpoints at 2008, 2013, and 2017) failed to
converge. A three-segment model (breakpoints: 2010
and 2016) was statistically significant (adjusted R-square:
0.96), based on an increasing linear segment running
from 2005 to 2010/11, a decreasing linear segment from
2010/11 to 2015/16, and then a steeper decreasing linear
segment from 2015/16 to 2020. A two-segment model
(breakpoint: 2012) was also statistically significant (R-
square: 0.94), based on an increasing linear segment
from 2005 to 2011, followed by a decreasing linear seg-
ment from 2011 to 2020. Of the models examined, the
three-segment model fit the observed data best with an
AIC value of 12.4, followed by the two-segment model
(AIC: 17.0).
Discussion
We characterized quantitative and qualitative patterns
and trends in medical opioid dispensing in Canada, with
focus on its ten provinces, for the period 2005–2020.
These analyses – extending previous Canada-based ex-
aminations - are worthwhile towards assessing both the
evolution and drivers of medical opioid utilization in
Canada as appear to represent and complete a distinct
‘era’, yet also more broadly given Canada’s status as a
global high-consumer nation [13, 50, 51].
The first, main observation is that over the study
period, Canada underwent a marked bi-partial evolution
– concretely a stark increase-to-decrease reversal pattern
- of strong opioid utilization. In aggregate, its strong opi-
oid utilization initially increased by almost 50 % (2005–
2011/12), and subsequently decreased by a similar pro-
portion (2011/12–2020) to an overall lower level com-
pared to 2005. In other words, the overall Canada-wide
population exposure for opioids first increased, and then
decreased by about half its total volume (in DDD),
within just a few years. Such a pronounced rise-and-fall
development in the system-wide utilization of controlled
psychotropic medications, or any medical intervention
geared to a chronic disease (here mainly: pain) with
overall stable prevalence in the population ought to be
considered highly unusual, if not exceptional. These de-
velopments naturally seek for analytic understanding
and contextualization of both the essential drivers be-
hind this starkly bi-directional pattern as well as their
impacts.
Our analyses begin at a point-in-time (2005) following
both increasing national and international attention to
‘chronic pain’ as a prevalent, but inadequately treated
health condition [1, 52–54]. These contexts, jointly with
the emergence of new medical practice guidelines advo-
cating for more liberal and generous opioid pharmaco-
therapy use especially in the context of pain care, and
the rapidly expanding availability of new and potent opi-
oid medications (e.g., slow-release oxycodone) evidently
facilitated a substantive increase in medical opioid pre-
scribing and expanding population exposure in Canada
within just a few years [7, 8, 51]. Yet, by the overall
‘peak’ in opioid utilization (2011/2012) it became both
increasingly evident that the safety and efficacy of strong
opioids widely used for pain-based pharmacotherapy
care had been mis-assessed, and that the extensive in-
creases in strong opioid prescribing were associated with
extensive collateral harms in the population [8, 21, 55].
Concretely, mounting evidence indicated substantive in-
creases in opioid-related non-medical use, morbidity
(e.g., hospitalizations) and mortality (e.g., poisoning
deaths) in Canada; for several of the main adverse out-
come indicators, strong correlations with population-
levels of prescription opioid dispensing were statistically
confirmed, meaning that these harm outcomes increased
in direct correlation with the changing volumes of opi-
oids available in the population [15, 56, 57].
As suggested by the results of our ‘segmented regres-
sion’ analyses, the timepoint of the pan-Canadian delist-
ing of slow-release oxycodone (‘Oxycontin’) from
provincial formularies (2012) as an initial, system-wide
intervention to reduce strong opioid availability marked
an initial major inversion point towards decreasing
strong opioid dispensing [23, 24]. This intervention re-
sulted in some lateral shifts in specific types of strong
opioids prescribed (e.g., from oxycodone to hydromor-
phone, fentanyl) yet appears to have triggered an overall
Fig. 3 Two- and three-segment models of ‘strong opioid’ utilization
in Canada, 2005–2020
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system-wide change and reduction effect in opioid
utilization. This particular intervention was further com-
plemented - depending on provincial setting or opioid
drug type - by a range of additional (many provincially-
based) restricting measures especially for high-risk opi-
oid utilization in subsequent years (e.g., prescription
monitoring program expansion, limitations on high-dose
formulations) as selectively assessed for their deceler-
ation impact, creating an aggregately more restrictive
opioid prescribing environment in Canada [22, 26, 50,
58–60].
The second ‘breakpoint’ identified, around 2016/17,
may be identified to coincide with the lead-up to and
the introduction of new Canadian guidelines for chronic
pain treatment tabled in 2017; these new guidelines
followed a corresponding set of new US-based guidelines
presented just somewhat earlier by the CDC [2016],
which already had received substantial attention and se-
lect regulatory uptake in Canadian jurisdictions (e.g.,
BC) with demonstrated reduction effects on opioid pre-
scribing [31, 61–63]. The new Canada-based guidelines
conveyed a paradigmatically different spirit and message
from their predecessors, advising towards a generally re-
strained and cautious, largely ‘last resort’ approach for
the utilization of strong opioid pharmacotherapy in the
context of pain care [64–67].
The stark inversion developments in strong opioid
utilization observed in Canada, to a substantial extent,
mirror developments in the US, where rising and excep-
tionally high levels of strong opioid dispensing reverted
to decrease following a combination intensified regula-
tory, monitoring and enforcement interventions [68–70].
Specifically, the implementation of the new CDC opioid
prescribing guideline (2016) has been assessed to be as-
sociated with significant decreases in opioid prescribing
in the US [71, 72]. While Canada traditionally has also
been a high-consumer country for codeine (‘weak’) opi-
oid products, the observed utilization patterns somewhat
follow those for strong opioids. Their utilization, some-
what similarly, also begins to decline around 2010/11, al-
beit without formal interventions but a rather
increasingly restrictive awareness and climate in the
medical-scientific community emphasizing their limited
efficacy and safety, and the subsequent need for reduc-
tions in utilization or for banning use altogether [73–
75].
Overall, the observed reversing patterns especially in
levels of strong opioid dispensing within just a few years
in Canada are remarkable, but also reflect the starkly
evolving, or even contradictory evidence that have been
informing and guiding related medical views and prac-
tices during this time. While available scientific literature
considered strong opioids as generally ‘effective and safe’
for pain therapy in the early 2000s, and their use was
systematically promoted by pharmaceutical producers
and prescribers alike on this basis, subsequently evolving
evidence increasingly underlined limitations and risks
[30, 76, 77]. Another influencing factor towards change
outside formal policy or regulatory measures involves
wider socio-cultural forces, for example, mass media or
investigative reports that have focused on the emerging
opioid crisis and its facets in Canada post-2012 [78].
These likely also contributed to changing broader public
awareness and vigilance, and professional practices in
regards to opioids and their use.
Further noteworthy based on the pharmaco-
epidemiologic data presented is the degree of heterogen-
eity specifically of province-based patterns and trends in
strong opioid dispensing in Canada over time. In any
given year, the range of inter-provincially highest and
lowest strong opioid dispensing levels reaches a differ-
ence of (nearly) 100 %. Of note, many - while not all - of
the ‘lows’ in strong opioid dispensing are recorded by
Quebec, Canada’s socio-culturally distinct francophone
province, whereas many ‘highs’ occurred in Ontario
(Quebec’s directly adjacent neighbor, and Canada’s most
populous province). Moreover, the patterns of strong
opioid dispensing in several – especially smaller Eastern
– provinces inverted to decreasing trends only with a
few years’ delay. While Canada is a confederation where
matters of health regulation and practice are predomin-
antly controlled by the provinces, such stark contrasts
within the same nation providing for principles of uni-
versal healthcare are worth underscoring [79]. Therefore,
the determinants of these inter-provincial differences
may include pronvincially-based regulatory system fac-
tors and differences (e.g., as related to provincial drug
formularies, medical practice regulations, prescription
drug monitoring etc.) but may also involve more ‘soft’
factors like medical practice culture, norms or training
[25, 80–82]. The drivers between these distinct intra-
Canadian heterogeneities in opioid utilization should be
more systematically examined by appropriate methods
and data.
The starkly contrasting patterns of opioid utilization in
Canada observed raise basic questions in regards to their
– direct and indirect - impacts and effects on relevant
health outcomes. While the initial increases in opioid
utilization were driven by high rates of chronic pain and
related care system deficiencies, there is discernably little
concrete evidence that the substantive expansions in
opioid utilization through the early 2000s has led to con-
crete improvements in pain care quality or outcomes
[17, 83–85]. The recently established (2018) ‘Canadian
Pain Task Force assesses a continuously unfavourable
and inadequate picture of the state of pain and related
care – characterizing it as “a public health emergency in
need of action” as recently as 2021 - that appears little
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different from the situation observed in the early 2000s
[35]. Conversely, various (mostly qualitative/local) stud-
ies have documented how current chronic pain patients
receiving opioid pharmacotherapy have been forced to
taper off their opioid medications, or experienced in-
creasing barriers towards opioid medications access in
contexts of recent, increasingly restrictive opioid control
environments [86–88]. Thus, the overall benefits of the
extensive expansions, and subsequent contraction of
strong opioid availability as a distinct chapter in health
policy practice in Canada appear to be marked by funda-
mental questions.
Moreover, the substantive un-intended adverse conse-
quences from extensively high population-level opioid
exposure, including high rates of non-medical opioid
use, opioid-related morbidity (hospitalizations, treatment
admissions) and especially mortality (poisoning fatalities)
including adverse impacts on population life expectancy
have entailed an exceptional burden of adverse outcomes
[15, 34, 89–92]. Most recently, Canada’s opioid-related
poisoning death rate rapidly rose from 7.8/100,000
(2016) to 17.0/100,000 (2020), translating to a total of
6,214 opioid-related fatalities in 2020 and indicating
similar rates to those recorded in the US [34, 93]. While
the dramatic increases in fatalities have been attributed
mostly to illicit/synthetic opioids, some analyses suggest
that these drugs proliferated partly in response to ‘supply
shocks/gaps’ following the rapid and substantive reduc-
tions in prescription opioid supply available for non-
medical use despite persistent demand [33, 94, 95]. On
this basis, the policy ‘case study’ of the marked inversion
of strong opioid utilization in Canada, as documented,
have come with distinctly mixed, including considerable
adverse impacts relevant for overall population health
[96, 97].
Further to the data presented, BC notably represents
an outlier province for recent developments in opioid
dispensing, in that it features marked re-increases in
strong opioid (i.e., morphine, hydromorphone)
utilization in very recent (2018–2020) years. These in-
creases appear mainly driven by a growing number of
‘safer opioid supply’ programs recently initiated in BC
(Vancouver) that provide individuals involved with high-
risk opioid (e.g., illicit fentanyl or analogues) exposure
with less toxic, prescription-grade strong opioid supply
(e.g., hydromorphone, sustained-release morphine pills)
as a public health measure towards reducing the acute
risk for opioid overdose and death [98–100]. On this
basis, somewhat ironically, strong opioid dispensing and
availability has been re-expanding mainly to remedy the
adverse public health consequences – directly or indir-
ectly - facilitated by previous over-exposure and subse-
quent rapid restrictions in pharmaceutical opioid supply
[94, 95, 97]. It also deserves mention that our data
extend to 2020, the first year of the COVID-19 pan-
demic, which has distinctly influenced psychoactive sub-
stance use and may have influenced prescription opioid
utilization patterns in different while uncertain ways in
that particular year. Specifically, there may have been in-
creased demand for or use of prescription opioids (e.g.,
for pain or other adverse symptoms) due to COVID-19
related circumstances, yet simultaneously increased ac-
cess barriers and practice changes to health care
provision may have reduced medication use [101–103].
The present study and analyses include several limita-
tions. The community-pharmacy sample-based data
used for opioid dispensing calculation does not capture
other dispensing points (e.g., hospitals, internet pharma-
cies), and so may involve underestimations. DDD as a
comparative opioid measurement metric is limited in re-
liability, but similar in its limitations to that of other
measures (e.g., morphine equivalents) and superior to
crude indicators like numbers of prescriptions [42, 104].
The segmented regression may be limited by the limited
number of data years available for the analyses. More-
over, segmented regression fits linear segments while it
is possible that in some cases non-linear segments could
provide a better fit for the data, a possibility not exam-
ined here. In addition, results can be influenced by the
choice of initial values but this is often mitigated by bas-
ing the selection on examination of initial scatter plots
[48]. The population-level dispensing data do not in-
clude the three Canadian territories, and so formally do
not represent the Canada ‘total’; however, the territories
only include < 0.5 % of the total Canadian population.
Analyses for Canada totals of opioid dispensing are
population-weighted, and so are dominated by trends in
the more populous (e.g., ON) provinces.
Conclusions
We have characterized an era of intensive rise-and-fall
in opioid dispensing, while featuring marked inter-
provincial heterogeneity, in Canada over the (brief)
period 2005–2020. This case study raises fundamental
questions for health policy making, and specifically opi-
oid medications utilization and control in contexts of
pain care, psychotropic medications use and public
health for Canada, but beyond for other jurisdictions
aiming to develop appropriate and effective health policy
approaches in these realms. Essentially, Canada in
regards to opioid utilization, after a pronounced period
of ‘up-and-down’, finds itself back where it was in the
early 2000s, yet without substantive evidence for marked
improvements in pain care quality or outcomes while re-
cording extensive adverse effects for public health from
extensive population-level opioid exposure. The stark os-
cillation developments observed, and related conse-
quences experienced over the past 20 years naturally
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cannot be corrected or reversed now. Looking forward,
it will be essential for Canada – within the complexities
of its health care and policy systems - to find a more
stable and evidence-informed state or equilibrium that
better balances evidence-based pain care and related
clinical opioid utilization needs for those individuals
who require them, while preventing undue opioid expos-
ure and reducing related adverse consequences for the
general population and the benefit of public health. To
some extent, other industrialized nations (e.g., select
European countries or New Zealand) have taken more
restrained and cautious approaches to medical opioid
utilization and – even in contexts of increases in
utilization - have experienced overall lower levels of re-
lated harms, and therefore may offer useful case studies
or guiding evidence to Canada or other jurisdictions in
these respects going forward [105–107].
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